Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Cervical Neoplasms 1NSCLC 1Lung Neoplasms 1Leukemia, Myeloid, Chronic-Phase 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 10Cisplatin 8Radiotherapy 6Magnetic Resonance Spectroscopy 6Carboplatin 6Specimen Handling 5Paclitaxel 5Brachytherapy 5Fluorodeoxyglucose F18 4dostarlimab 3atezolizumab 3Trastuzumab 3Radiation 3Platinum 3Nivolumab 3Human Papillomavirus DNA Tests 3Docetaxel 3Colposcopy 31,2-diaminocyclohexaneplatinum II citrate 3zimberelimab 2tislelizumab 2spartalizumab 2olaparib 2human papillomavirus vaccine, L1 type 16, 18 2durvalumab 2Vaccines 2Surveys and Questionnaires 2Standard of Care 2Robotic Surgical Procedures 2Radiotherapy, Intensity-Modulated 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Uterine Cervical Neoplasms × Tyrosine Kinase Inhibitors × Clear all
NCT05824468 2026-03-10

Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer

Sun Yat-sen University

Phase 2 Active not recruiting
30 enrolled
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡